ASHLEY CAGLE: Open Payments
NPI 1265152326 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,204 in 59 payments from 16 companies in 2025. Trend: 2023 $2,680 · 2024 $2,589 · 2025 $1,204
Food & beverage: $1,204
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $365 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $154 |
| Janssen Biotech, Inc. | 5 | $116 |
| Lilly USA, LLC | 4 | $89 |
| QOL Medical, LLC | 4 | $83 |
| GENZYME CORPORATION | 3 | $80 |
| Gilead Sciences, Inc. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| Radius Health, Inc. | 2 | $53 |
| Intercept Pharmaceuticals, Inc. | 2 | $39 |
Products named: CREON, XIFAXAN, TREMFYA, Sucraid, DUPIXENT, SKYRIZI, OMVOH, LINZESS.
Industry payments across LA — which companies pay providers there.
